MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

Medicines beginning with M

Methylprednisolone

Methylprednisolone 2mg tablets

Use with caution

Stability notes for Methylprednisolone 2mg tablets

Protect from light Anecdotal reports of use in MCAs (low quality evidence)

Provenance

This recommendation is based on the products Medrone 2mg tablets (Pfizer Limited).

Supplier

Medrone 2mg tablets (Pfizer Ltd)

Methylprednisolone 4mg tablets

Use with caution

Stability notes for Methylprednisolone 4mg tablets

Protect from light Anecdotal reports of use in MCAs (low quality evidence)

Provenance

This recommendation is based on the product Medrone 4mg tablets (Pfizer Limited).

Supplier

Medrone 4mg tablets (Pfizer Ltd)

Methylprednisolone 16mg tablets

Use with caution

Stability notes for Methylprednisolone 16mg tablets

Protect from light Anecdotal reports of use in MCAs (low quality evidence)

Provenance

This recommendation is based on the product Medrone 16mg tablets (Pfizer Limited).

Supplier

Medrone 16mg tablets (Pfizer Ltd)

Methylprednisolone 100mg tablets

Use with caution

Stability notes for Methylprednisolone 100mg tablets

Protect from light Anecdotal reports of use in MCAs (low quality evidence)

Provenance

This recommendation is based on the products Medrone 100mg tablets (Pfizer Limited).

Suppliers

Medrone 100mg tablets (Abacus Medicine Ltd)
Medrone 100mg tablets (Pfizer Ltd)
Medrone 100mg tablets (Sigma Pharmaceuticals Plc)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.